SG10201500208SA - Npp1 fusion proteins - Google Patents

Npp1 fusion proteins

Info

Publication number: SG10201500208SA
Authority: SG; Singapore
Prior art keywords: fusion proteins; npp1 fusion; npp1; proteins; fusion
Prior art date: 2010-03-12

Application number

SG10201500208SA

Inventor

Anthony Quinn

Alex J Harvey

Zhinan Xia

Original Assignee

Synageva Biopharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-12

Filing date

2011-09-15

Publication date

2015-03-30

2011-09-15 Application filed by Synageva Biopharma Corp filed Critical Synageva Biopharma Corp

2015-03-30 Publication of SG10201500208SA publication Critical patent/SG10201500208SA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04001—Phosphodiesterase I (3.1.4.1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Immunology (AREA)
Neurology (AREA)
Vascular Medicine (AREA)

SG10201500208SA 2010-03-12 2011-09-15 Npp1 fusion proteins SG10201500208SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34006610P	2010-03-12	2010-03-12
PCT/US2011/028233 WO2011113027A2 (en)	2010-03-12	2011-03-11	Npp1 fusion proteins

Publications (1)

Publication Number	Publication Date
SG10201500208SA true SG10201500208SA (en)	2015-03-30

Family

ID=44564171

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10202100341XA SG10202100341XA (en)	2010-03-12	2011-09-15	Npp1 fusion proteins
SG10201500208SA SG10201500208SA (en)	2010-03-12	2011-09-15	Npp1 fusion proteins

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG10202100341XA SG10202100341XA (en)	2010-03-12	2011-09-15	Npp1 fusion proteins

Country Status (10)

Country	Link
US (7)	US8846603B2 (en)
EP (1)	EP2545080B1 (en)
JP (3)	JP5735665B2 (en)
BR (1)	BR112013023010B1 (en)
CL (1)	CL2013002607A1 (en)
ES (2)	ES2628841T3 (en)
NZ (1)	NZ615070A (en)
SG (2)	SG10202100341XA (en)
TR (1)	TR201903573T4 (en)
WO (1)	WO2011113027A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2628841T3 (en)	2010-03-12	2017-08-04	Alexion Pharmaceuticals, Inc.	Npp1 fusion proteins
HUE048688T2 (en)	2010-09-09	2020-08-28	Alexion Pharma Inc	Isolated recombinant human n-glycosylated lysosomal acid lipase
WO2012112681A1 (en)	2011-02-15	2012-08-23	Shire Human Genetic Therapies, Inc.	Methods for treating lysosomal acid lipase deficiency
SG193024A1 (en) *	2011-03-11	2013-10-30	Synageva Biopharma Corp	Npp1 fusion proteins
JP6894664B2 (en)	2013-02-13	2021-06-30	イエールユニバーシティ	Compositions and methods for treating pathological calcification and ossification
WO2014182666A1 (en) *	2013-05-06	2014-11-13	Bio-Rad Laboratories, Inc.	Stabilization of labile analytes in reference materials
USRE49529E1 (en) *	2014-12-19	2023-05-16	Inozyme Pharma, Inc.	Methods of treating tissue calcification
ES2983910T3 (en) *	2015-05-19	2024-10-28	Univ Yale	Compositions for treating pathological calcification conditions and methods using them
AU2016355715A1 (en) *	2015-11-20	2018-05-31	Yale University	Compositions for treating ectopic calcification disorders, and methods using same
EP3471747A1 (en)	2016-06-16	2019-04-24	Alexion Pharmaceuticals, Inc.	Methods of treating myointimal proliferation
EP3493829B1 (en) *	2016-08-05	2024-04-17	Yale University	Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
CA3096821A1 (en)	2017-09-27	2019-04-04	Inozyme Pharma, Inc.	Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
CN112930397A (en) *	2018-08-31	2021-06-08	耶鲁大学	ENPP1 polypeptides and methods of use thereof
JP2023529892A (en)	2020-06-09	2023-07-12	イノザイムファーマインク．	Soluble ENPP1 or ENPP3 protein and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
US4935233A (en)	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
US6825396B2 (en)	1996-06-12	2004-11-30	Board Of Trustees Operating Michigan State University	Methods for tissue specific synthesis of protein in eggs of transgenic hens
EP0967999A2 (en)	1997-02-14	2000-01-05	The Salk Institute For Biological Studies	Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
US20040019923A1 (en)	1997-10-16	2004-01-29	Ivarie Robert D.	Exogenous proteins expressed in avians and their eggs
EP2133421A1 (en)	1997-10-16	2009-12-16	University Of Georgia Research Foundation, Inc.	Transgenic birds and protein production in the egg white
EP1032662B1 (en)	1997-11-07	2006-03-08	Trillium Therapeutics Inc.	Methods and compositions for immunomodulation
DE20121960U1 (en)	2000-04-06	2004-01-15	Epigenomics Ag	New nucleic acid derived from chemically treated metastasis genes, useful for diagnosis of cancers by analysis of cytosine methylation, also for treatment
US20020108132A1 (en)	2001-02-02	2002-08-08	Avigenics Inc.	Production of a monoclonal antibody by a transgenic chicken
US7294507B2 (en)	2001-11-30	2007-11-13	Avigenics, Inc.	Ovomucoid promoters and methods of use
US6875588B2 (en)	2001-11-30	2005-04-05	Avigenics, Inc.	Ovomucoid promoter and methods of use
US7858297B2 (en)	2001-12-18	2010-12-28	Centre National De La Recherche Scientifique Cnrs	Chemokine-binding protein and methods of use
AU2003213246A1 (en)	2002-02-21	2003-09-09	University Of Virginia Patent Foundation	Bone targeting peptides
US20050090001A1 (en)	2003-10-07	2005-04-28	Parker Stephen H.	Cell lines and methods for producing proteins
CA2559228C (en)	2004-04-21	2016-06-21	Enobia Pharma Inc.	Bone delivery conjugates and method of using same to target proteins to bone
US20060074225A1 (en) *	2004-09-14	2006-04-06	Xencor, Inc.	Monomeric immunoglobulin Fc domains
GB0426397D0 (en) *	2004-12-01	2005-01-05	Health Prot Agency	Fusion proteins
US20090180989A1 (en) *	2005-10-05	2009-07-16	Synageva Biopharma Corp.	Compositions and methods for delivering nucleotide sequences to vertebrates
SI2368999T1 (en)	2007-05-11	2014-07-31	Alexion Pharma Holding,	Bone targeted alkaline phosphatase, kits and methods of use thereof
PE20100141A1 (en) *	2008-05-23	2010-02-22	Wyeth Corp	BINDING PROTEIN TO THE INTERLEUQUIN RECEPTOR 21
ES2628841T3 (en)	2010-03-12	2017-08-04	Alexion Pharmaceuticals, Inc.	Npp1 fusion proteins

2011
- 2011-03-11 ES ES11754231.6T patent/ES2628841T3/en active Active
- 2011-03-11 EP EP11754231.6A patent/EP2545080B1/en active Active
- 2011-03-11 US US13/583,973 patent/US8846603B2/en active Active
- 2011-03-11 WO PCT/US2011/028233 patent/WO2011113027A2/en active Application Filing
- 2011-09-15 BR BR112013023010-0A patent/BR112013023010B1/en active IP Right Grant
- 2011-09-15 SG SG10202100341XA patent/SG10202100341XA/en unknown
- 2011-09-15 SG SG10201500208SA patent/SG10201500208SA/en unknown
- 2011-09-15 TR TR2019/03573T patent/TR201903573T4/en unknown
- 2011-09-15 ES ES11861101T patent/ES2716526T3/en active Active
- 2011-09-15 NZ NZ615070A patent/NZ615070A/en not_active IP Right Cessation
- 2011-09-15 US US14/004,294 patent/US20140154774A1/en not_active Abandoned
- 2011-09-15 JP JP2013557704A patent/JP5735665B2/en active Active
2013
- 2013-09-10 CL CL2013002607A patent/CL2013002607A1/en unknown
2014
- 2014-08-01 US US14/449,364 patent/US9540621B2/en active Active
- 2014-10-06 US US14/507,124 patent/US20150024460A1/en not_active Abandoned
2015
- 2015-04-16 JP JP2015084216A patent/JP6096826B2/en active Active
2017
- 2017-01-27 US US15/417,590 patent/US20170145393A1/en not_active Abandoned
- 2017-02-16 JP JP2017026961A patent/JP6484905B2/en active Active
2020
- 2020-11-25 US US17/105,245 patent/US20210301268A1/en not_active Abandoned
2022
- 2022-08-11 US US17/819,065 patent/US20230129977A1/en active Pending

Also Published As

Publication number	Publication date
US9540621B2 (en)	2017-01-10
BR112013023010A2 (en)	2018-07-03
JP2015164427A (en)	2015-09-17
US20130273021A1 (en)	2013-10-17
CL2013002607A1 (en)	2014-03-28
ES2716526T3 (en)	2019-06-13
WO2011113027A3 (en)	2012-03-01
JP6096826B2 (en)	2017-03-15
US20140154774A1 (en)	2014-06-05
US20170145393A1 (en)	2017-05-25
JP6484905B2 (en)	2019-03-20
JP5735665B2 (en)	2015-06-17
JP2017137318A (en)	2017-08-10
US20150024460A1 (en)	2015-01-22
US20140377859A1 (en)	2014-12-25
ES2628841T3 (en)	2017-08-04
EP2545080A2 (en)	2013-01-16
US8846603B2 (en)	2014-09-30
EP2545080A4 (en)	2013-09-11
EP2545080B1 (en)	2017-05-10
SG10202100341XA (en)	2021-02-25
US20230129977A1 (en)	2023-04-27
NZ615070A (en)	2015-10-30
BR112013023010B1 (en)	2022-05-10
US20210301268A1 (en)	2021-09-30
WO2011113027A2 (en)	2011-09-15
TR201903573T4 (en)	2019-04-22
JP2014509851A (en)	2014-04-24

Publication	Publication Date	Title
HRP20150241T1 (en)	2015-06-05	Anticancer fusion protein
EP2616896A4 (en)	2016-10-19	Sensor fusion
EP2638072A4 (en)	2014-05-07	Fusion proteins for hiv therapy
HK1192587A1 (en)	2014-08-22	Therapeutic fusion proteins
SG10202100341XA (en)	2021-02-25	Npp1 fusion proteins
EP2634188A4 (en)	2014-05-07	Fused aminodihydropyrimidine derivative
HUE048848T2 (en)	2020-08-28	Fusion proteins & combination vaccines
HK1186192A1 (en)	2014-03-07	Anticancer fusion protein
IL226481A0 (en)	2013-07-31	Fusion enzymes
EP2683742A4 (en)	2014-08-06	Npp1 fusion proteins
ZA201300066B (en)	2014-03-26	Fusion protein having factor vii activity
EP2698386A4 (en)	2014-12-03	Fusion protein
HK1187369A1 (en)	2014-04-04	Fusion protein for secretory protein expression
EP2657337A4 (en)	2014-09-17	Fusion protein
GB201016494D0 (en)	2010-11-17	Polypeptide
EP2521787A4 (en)	2013-11-13	Enhanced protein expression
ZA201207425B (en)	2014-03-26	Fusion protein
GB201007834D0 (en)	2010-06-23	Growth promoting fusion proteins
GB201007955D0 (en)	2010-06-30	Somatosatin fusion proteins
GB201114701D0 (en)	2011-10-12	Fusion proteins
GB201107189D0 (en)	2011-06-15	Fusion proteins
GB201010202D0 (en)	2010-07-21	Fusion polypeptides
GB201004150D0 (en)	2010-04-28	Modified receptor fusion proteins
GB201007550D0 (en)	2010-06-23	Modified receptor fusion proteins
PL393146A1 (en)	2012-06-04	Anticancer fusion protein